Navigation Links
Researchers show that nitric oxide-donating naproxen can boost colorectal cancer prevention
Date:4/21/2010

WASHINGTON, D.C. (April 21, 2010)Past randomized clinical trials have shown that non-steroidal anti-inflammatory drugs (NSAIDs), including naproxen, can reduce the risk of colon cancer and precancerous polyps in humans. Now, researchers at Fox Chase Cancer Center have found that an investigational form of naproxen, called nitric oxide-donating naproxen (NO-naproxen), can block one of the earliest molecular changes that lead to colorectal cancer development while also reducing gastrointestinal toxicity, a relatively common side effect associated with NSAIDs.

"It appears that the investigational form of naproxen we studied may be more effective than standard naproxen in inhibiting colorectal tumor development," says Margie Clapper, Ph.D., Co-Leader of the Cancer Prevention and Control Program at Fox Chase Cancer Center. "An added benefit would be the reduced gastrointestinal toxicity of this novel type of naproxen." Clapper's group will present the new data at the 2010 annual meeting of the American Association for Cancer Research.

"This new form of naproxen is probably more protective because it blocks one of the first steps in the colorectal cancer-causing pathway," she says.

Previous work from Clapper and others has shown that increased activity of the WNT/-catenin pathway is one of the earliest events in colorectal cancer formation. To test whether NO-naproxen could reduce activation of the pathway, the team used colon cancer cells that become bioluminescent when the WNT/-catenin pathway is active. They found that cells treated with NO-naproxen had about 50% less bioluminescence than cells treated with naproxen.

"The major and novel finding from the study is that the NO-naproxen can alter a particular signaling pathway that is one of the earliest events in colon cancer formation," Clapper says. "Based on the in vitro data, we think that NO-naproxen is much better than naproxen in nipping this whole process in the bud."

To confirm the in vitro results, the team has treated mice that are genetically predisposed to develop colorectal adenomas with NO-naproxen and naproxen and are awaiting the results of this study.

NSAIDs have been shown to reduce the risk of colon cancer and precancerous polyps in people. However, some of the agents have been taken off the market due to cardiovascular toxicity. With that in mind, Clapper says, "If we can find something in the same arena that is effective and nontoxic, it will be extremely valuable."

NO-naproxen and other NO-donating NSAID derivatives are a new class of agents being developed with the aim of reducing gastrointestinal toxicity, a relatively common side effect associated with NSAIDs.


'/>"/>

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. Vitamin K may protect against developing non-Hodgkins lymphoma, say Mayo Clinic researchers
2. UAB researchers find 4 biomarkers important in colorectal cancer treatment prognosis
3. UAB researchers find 4 biomarkers important in colerectal cancer treatment prognosis
4. USC researchers discover new molecular subtype of brain cancer
5. Plant pathogen genetically tailors attacks to each part of host, say Stanford researchers
6. Researchers find compound effective in destroying antibiotic-resistant biofilms
7. Boston researchers lead $15 million federal research grant to support advancement of health IT
8. Researchers discover new approach for identifying smokers at highest risk for developing lung cancer
9. Researchers aim for consensus on measuring the impact of visual impairment
10. Researchers Boost Post-Heart Attack Survival in Mice
11. Researchers quantify benefits of minimally invasive removal of hard-to-reach tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... (PRWEB) May 24, 2016 -- Grow Healthy ... Advisory Board. Joining the Grow Healthy Advisory Board team are ... embody the mission of our organization and bring talent, expertise and ... as we continue to expand our footprint as the leader in ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... choose the perfect data logger for each job, ensuring the best suited solution ... calibrations of MadgeTech data loggers at their lab in Istanbul. , Metroloji Okulu ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... and clinical practice of radiosurgery, is recognizing five medical residents and students for ... stereotactic body radiotherapy (SBRT). The awards will be presented at the 2016 SRS/SBRT ...
(Date:5/24/2016)... ... May 24, 2016 , ... Bio-Logic Aqua® Research ... forty years and a trainer for Ageless Grace ( http://www.agelessgrace.com ) to discuss ... on May 16, 2016. , Formerly a Northwestern University Literature Professor, Kinst gravitated ...
(Date:5/24/2016)... , ... May 24, 2016 , ... In light of ... aware of the potential of contaminated well water throughout the Houston area. , Heavy ... with well water that’s exposed to contaminants. Residents may not even be aware of ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)...   , Study met ... and superiority in , Excellent plus ... of the ascending colon   , ... B.V. today announced new positive data from the phase III MORA ... standard 2 litre PEG with ascorbate. The study met both primary ...
(Date:5/24/2016)... Celsion Corporation (NASDAQ: CLSN ... an update on its ongoing OVATION study, a ... the Company,s DNA-based immunotherapy, with the standard of ... advanced ovarian cancer who will undergo neoadjuvant chemotherapy ... IL-12 DNA plasmid vector formulated as a nanoparticle ...
(Date:5/24/2016)... KONG , May 24, 2016 /PRNewswire/ ... COMBO ™ , la première ... des cathéters destinés à l,intervention portant sur ... (FAV)   OrbusNeich, entreprise mondiale ... permettant de changer la vie, a élargi ...
Breaking Medicine Technology: